Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Donna Mildvan

Showing results (11-20 of 48) with videos related to

Pageof 5
Sort By:
American Journal of Infection Control|April 30, 2014
Fluoroquinolone- and ceftriaxone-based therapy of community-acquired pneumonia in hospitalized patients: the risk of subsequent isolation of multidrug-resistant organismsRobert C Goldstein, Gregg Husk, Tomasz Jodlowski, et al.
American Journal of Public Health|February 19, 2011
The effect of peer-driven intervention on rates of screening for AIDS clinical trials among African Americans and HispanicsMarya Viorst Gwadz, Noelle R Leonard, Charles M Cleland, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|May 1, 2002
Pharmacokinetic interaction between nevirapine and ethinyl estradiol/norethindrone when administered concurrently to HIV-infected womenDonna Mildvan, Robert Yarrish, Ann Marshak, et al.
Diagnostic Microbiology and Infectious Disease|August 16, 2011
Methicillin-susceptible Staphylococcus aureus nasal colonization and the risk of subsequent methicillin-resistant Staphylococcus aureus infections among hospitalized patientsJörg J Ruhe, Leonidez de Guzman, Marie Moss, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 4, 2008
Intranasal transmission of hepatitis C virus: virological and clinical evidenceSagiv Aaron, James M McMahon, Danielle Milano, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 1, 2005
Serum neopterin, an immune activation marker, independently predicts disease progression in advanced HIV-1 infectionDonna Mildvan, John Spritzler, Sidney E Grossberg, et al.
AIDS and Behavior|May 29, 2012
Predictors of screening for AIDS clinical trials among African-Americans and Latino/Hispanics enrolled in an efficacious peer-driven intervention: uncovering socio-demographic, health, and substance use-related factors that promote or impede screeningMarya Gwadz, Charles M Cleland, Noelle R Leonard, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 9, 2003
Can immune markers predict subsequent discordance between immunologic and virologic responses to antiretroviral therapy? Adult AIDS Clinical Trials GroupJohn Spritzler, Donna Mildvan, Aleksandra Russo, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 18, 2002
Abacavir expanded access program for adult patients infected with human immunodeficiency virus type 1Harold A Kessler, Judy Johnson, Stephen Follansbee, et al.
AIDS Research and Therapy|April 14, 2005
Monitoring processed, mature Human Immunodeficiency Virus type 1 particles immediately following treatment with a protease inhibitor-containing treatment regimenHeather A Baird, Andre J Marozsan, Michael M Lederman, et al.
Pageof 5

Showing results (11-20 of 48) with videos related to

Sort By:
Pageof 5
American Journal of Infection Control|April 30, 2014
Fluoroquinolone- and ceftriaxone-based therapy of community-acquired pneumonia in hospitalized patients: the risk of subsequent isolation of multidrug-resistant organismsRobert C Goldstein, Gregg Husk, Tomasz Jodlowski, et al.
American Journal of Public Health|February 19, 2011
The effect of peer-driven intervention on rates of screening for AIDS clinical trials among African Americans and HispanicsMarya Viorst Gwadz, Noelle R Leonard, Charles M Cleland, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|May 1, 2002
Pharmacokinetic interaction between nevirapine and ethinyl estradiol/norethindrone when administered concurrently to HIV-infected womenDonna Mildvan, Robert Yarrish, Ann Marshak, et al.
Diagnostic Microbiology and Infectious Disease|August 16, 2011
Methicillin-susceptible Staphylococcus aureus nasal colonization and the risk of subsequent methicillin-resistant Staphylococcus aureus infections among hospitalized patientsJörg J Ruhe, Leonidez de Guzman, Marie Moss, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 4, 2008
Intranasal transmission of hepatitis C virus: virological and clinical evidenceSagiv Aaron, James M McMahon, Danielle Milano, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 1, 2005
Serum neopterin, an immune activation marker, independently predicts disease progression in advanced HIV-1 infectionDonna Mildvan, John Spritzler, Sidney E Grossberg, et al.
AIDS and Behavior|May 29, 2012
Predictors of screening for AIDS clinical trials among African-Americans and Latino/Hispanics enrolled in an efficacious peer-driven intervention: uncovering socio-demographic, health, and substance use-related factors that promote or impede screeningMarya Gwadz, Charles M Cleland, Noelle R Leonard, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 9, 2003
Can immune markers predict subsequent discordance between immunologic and virologic responses to antiretroviral therapy? Adult AIDS Clinical Trials GroupJohn Spritzler, Donna Mildvan, Aleksandra Russo, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 18, 2002
Abacavir expanded access program for adult patients infected with human immunodeficiency virus type 1Harold A Kessler, Judy Johnson, Stephen Follansbee, et al.
AIDS Research and Therapy|April 14, 2005
Monitoring processed, mature Human Immunodeficiency Virus type 1 particles immediately following treatment with a protease inhibitor-containing treatment regimenHeather A Baird, Andre J Marozsan, Michael M Lederman, et al.
Pageof 5